Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 4/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.35 |
| ▸ | CCR2 | P41597 | 3/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31166007 | 0.79 | RAPGEF4 (0.40) | CYP3A4ACLYKDM1AMAOAKMT2A | |
| SCHEMBL18332101 | 0.79 | KDM1A (0.51) | PSIP1ADRA2CADRA1AADRA1BKDM1A | |
| Ammonia Solution, Strong SCHEMBL2211253 | 0.77 | KDM1A (0.50) | ADRA2CADRA1AADRA1BKDM1AMAOA | |
| SCHEMBL17526277 | 0.75 | BRD4 (0.39) | ACLYKDM1AMAOA | |
| SCHEMBL2209213 | 0.72 | ADRA2C (0.43) | ADRA2CADRA1AADRA1BKMT2A | |
| SCHEMBL2211141 | 0.71 | CA1 (0.42) | PSIP1PTGES2 | |
| SCHEMBL13529173 | 0.71 | ALDH1A1 (0.39) | PSIP1CYP3A4 | |
| SCHEMBL16441841 | 0.69 | CCR2 (0.55) | ACLYCCR2KMT2A | |
| SCHEMBL28021196 | 0.68 | PSIP1 (0.62) | PSIP1CYP3A4CYP2C9CYP2C19ACLY | |
| SCHEMBL23226753 | 0.68 | ADRB3 (0.40) | CYP3A4CYP2C9CYP2C19PTGES2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981883-B2 | Substituted spiro-compounds and the use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | REN, PKD1, PKD2 | PSIP1 858/4885CYP3A4 73/4885CYP2C9 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.